Dr. Aki Morikawa, MD

Dr. Morikawa practices at University Hospital in Ann Arbor, Michigan.

Dr. Morikawa's NPI, 1659539179, was assigned on May 30, 2008. Dr. Morikawa graduated from Emory University School of Medicine in 2008. Dr. Morikawa holds Michigan license 4301105870.

Dr. Morikawa's primary practice is University Hospital, at 1500 E Medical Center Dr, Ann Arbor, MI 48109. The practice phone is (734) 936-4000.

Dr. Morikawa's primary practice is University Hospital in Ann Arbor, Michigan. Dr. Morikawa is also affiliated with University Hospital. The medical group on file is University of Michigan Health. Dr. Morikawa's employer is on file too: a school & student health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Morikawa practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Morikawa's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Morikawa's licenses on file in 3 states: Michigan, Georgia and New York.

CMS data shows 162 Medicare services from Dr. Morikawa across 6 procedure codes in 2024, for 85 Medicare patients. Medicare paid $9,510 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 85 Medicare patients who saw Dr. Morikawa in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have cancer, and 72% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Morikawa's median patient age at 61, with 91% women.

In 2024, Dr. Morikawa wrote 210 Medicare Part D claims for 72 patients. 85% of them were for generic drugs. CMS names the drug for 125 of them, across 3 drugs with 11 or more claims each, at $5,818 in total drug cost. In 2023, CMS named 127 claims across 4 drugs.

Dr. Morikawa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Morikawa as offering telehealth.

Dmand AI links 28 papers to Dr. Morikawa, published from 2014 to 2025. 2022 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Brain Neoplasms and Receptor, ErbB-2. Dr. Morikawa has published most often in Breast Cancer Res Treat. Dr. Morikawa's most frequent co-authors are Andrew D. Seidman, MD, Sofia Diana Merajver, MD, PhD and Jason Anthony Heth, MD.

Dmand AI links Dr. Morikawa to 6 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Brain Neoplasms, Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 12 general payments to Dr. Morikawa from 6 drug and device companies from 2019 to 2021. Consulting fees make up the largest share, 94% of the total. Taiho Oncology, Inc. paid the most, $5,158.

Dr. Morikawa graduated from Emory University School of Medicine in 2008.